Trevogrumab

Trevogrumab binds circulating mature myostatin with high affinity and selectivity, preventing it from engaging activin type II receptors. Unlike ACE-031 it does not touch activins or BMPs, and unlike apitegromab it acts on the mature ligand rather than its precursor. On its own in earlier sarcopenia work it produced only modest gains, which is broadly true of every myostatin-selective agent tested in people who are not losing muscle for a specific reason. Its current thesis is much sharper: during GLP-1-driven weight loss roughly a third of the weight lost is lean mass, and blocking myostatin during that window changes the composition of what is lost. In the phase 2 COURAGE trial, adding trevogrumab to semaglutide prevented about half of that lean mass loss and increased fat loss at the same time. Adding the anti-activin A antibody garetosmab on top pushed lean mass preservation higher again, at the cost of more discontinuations.

Targets: Myostatin (GDF-8), Activin type II receptor signalling (indirectly)

• · 200 mg and 400 mg fixed doses (200,000 and 400,000 mcg). The 400 mg arm had a higher discontinuation rate - 10.6% versus 4.7% at 200 mg and 4.6% for semaglutide alone.

Work out your exact syringe units →

• commonInjection-site reactions
• commonGastrointestinal effects— Difficult to separate from semaglutide's own profile in the combination arms.
• commonTreatment discontinuation at the higher dose— 10.6% at 400 mg versus 4.6% on semaglutide alone - the dose-response on tolerability is real.
• uncommonAnti-drug antibodies

• Pregnancy and breastfeeding.
• Known hypersensitivity.
• No legitimate access outside a clinical trial.

• synergysemaglutide — The entire premise - roughly half of semaglutide's lean mass loss was prevented, with 17.8% and 15.1% greater fat reduction in the lower and higher dose arms.
• redundantbimagrumab — Competing approaches to the same problem.
• redundantapitegromab — Both selectively target myostatin, at different points in its activation.

• · DEXA body composition is the only meaningful endpoint here - total weight loss is not the point.
• · Standard biologic safety labs.
• · Grip strength or functional testing to check that preserved mass is functional mass.

Investigational only, not approved anywhere. Prohibited in sport at all times by WADA.

• Phase 2 COURAGE trial results presented at EASD 2025 - trevogrumab with or without garetosmab plus semaglutide in obesity (trial)
• Earlier phase 2 studies of REGN1033 in sarcopenia (trial)

Trevogrumab is a fully human antibody that neutralises mature myostatin directly, and the interesting thing about it is less the molecule than the development strategy wrapped around it. Latres showed in aged mice that REGN1033 increased muscle mass and force, working through the expected route: sequestering mature myostatin prevents ActRIIB engagement, ALK4/ALK5 never phosphorylate Smad2/3, the FoxO-linked ubiquitin ligase programme is not transcribed, and Akt-mTORC1 activity rises. Salzler's proteomic comparison of myostatin-deficient mice against REGN1033-treated animals is a useful sanity check on how completely pharmacological blockade reproduces genetic deletion - it does not, entirely, which is worth knowing before anyone extrapolates from double-muscled cattle. What makes trevogrumab strategically important is COURAGE. Regeneron enrolled 1005 patients with obesity into a phase 2 study of trevogrumab, with or without garetosmab, added to semaglutide. Garetosmab is an anti-activin A antibody. Running the two together is deliberately reconstructing the breadth of blockade that ACE-031 achieved with a single promiscuous trap, but doing it one defined ligand at a time so that the contribution and the toxicity of each can be attributed. Part B's co-primary endpoints are percent change in total fat mass and percent change in total lean mass at 26 weeks, which is exactly the question this whole class exists to answer: when you take 15% of someone's body weight off with an incretin, how much of it has to be muscle. At 1005 participants it is the largest trial of a myostatin-targeting agent ever run.

The honest position on trevogrumab is that its human data are not yet public. COURAGE is enrolled and active but not reporting, so everything above the preclinical level is design rather than result. Salzler's proteomics is the specific caution worth internalising: myostatin deficiency and pharmacological myostatin blockade do not produce the same muscle. A lifetime of genetic absence during development is not reproducible by an antibody given to an adult, and the mental model built from Belgian Blue cattle and the myostatin-mutant child described by Schuelke is misleading when applied to a drug. Beyond that, this is a fully human monoclonal antibody in phase 2 development, with no legitimate access outside the trial and no realistic grey-market production route. The practical hazard is not the drug, it is anything sold under its name.

• Mature myostatin (GDF-8) — High-affinity neutralising binding; exact Kd not published in the sources resolved here

  Prevents ActRIIB engagement by the active ligand, removing Smad2/3-driven suppression of muscle protein synthesis.

• GDF11 — Not established. GDF11 is roughly 90% identical to myostatin in the mature domain, so selectivity is a genuine engineering achievement rather than a given, and the degree achieved by trevogrumab was not resolved here.

  If cross-reactive, GDF11 blockade would broaden the effect and the risk. Unresolved.

• Activin A — Not bound by trevogrumab - it is the target of garetosmab, the separate antibody used alongside it in COURAGE

  None from trevogrumab alone. In the combination arms, activin A blockade is added deliberately as a second agent.

• COURAGE - A Randomized, Double-Blind Study of the Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity (NCT06299098) Phase 2 · n=1005 · 26 weeks

  Part A: incidence and severity of treatment-emergent adverse events from baseline to week 7. Part B: percent change in total fat mass and percent change in total lean mass from baseline to week 26, across eight arms combining semaglutide with moderate-high or high dose trevogrumab, with or without garetosmab. Part C adds low and moderate subcutaneous trevogrumab doses. Quadruple-masked, randomised. Listed as active, not recruiting on ClinicalTrials.gov.

Not established in humans. The trial's functional endpoints sit at week 26, and its safety endpoints at week 7. Preclinically, muscle mass changes in mice developed over weeks of dosing.

Trevogrumab's entire clinical identity is a stack. It is being developed on top of semaglutide, and in half the COURAGE arms on top of semaglutide plus garetosmab as well. The rationale is that GLP-1-driven weight loss costs lean mass, myostatin blockade defends it, and adding activin A blockade extends the defence at the cost of the activin-related adverse effects that broad blockade brings. Running trevogrumab with any other agent that hits this pathway - bimagrumab, apitegromab, ACE-031, follistatin - is redundant at best. The combination with garetosmab specifically is the one to think carefully about, because it reintroduces activin A blockade and with it FSH suppression and the broader endocrine surface that selective anti-myostatin agents avoid.

Against apitegromab: both are anti-myostatin antibodies, but they intervene at different points - apitegromab prevents activation of the latent precursor, trevogrumab neutralises the mature ligand. Apitegromab has a positive phase 3 in SMA and a completed obesity phase 2; trevogrumab has the largest trial in the class still running. Against bimagrumab: bimagrumab blocks the receptors and therefore all the ligands at once, and its published effect on body composition is larger. Trevogrumab's combination with garetosmab is Regeneron approaching the same breadth from the other direction, adding one antibody at a time so the contribution of each ligand can be attributed - which is a scientifically better design than a promiscuous trap even if the endpoint is similar. Against ACE-031, which achieved broad blockade with one molecule and was stopped for telangiectasia, the modular antibody approach exists precisely so that if a vascular signal appears you know which ligand caused it.

Investigational and not marketed. No price exists.

• ?No human efficacy or safety results are published. COURAGE is active but not reporting.
• ?No published pharmacokinetic parameters - half-life, clearance, volume of distribution or bioavailability - were resolved.
• ?The degree of selectivity against GDF11 is unresolved, and GDF11 shares roughly 90% mature-domain identity with myostatin, so this is a real question rather than a formality.
• ?Binding affinity for mature myostatin was not published in the sources reviewed.
• ?The antibody isotype is not confirmed here beyond it being a fully human monoclonal.
• ?Whether the trevogrumab-plus-garetosmab arms reproduce the vascular adverse effects seen with broad ActRIIB trapping is exactly what the trial is designed to find out, and is currently unknown.

• Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, Huang Y, Eckersdorff M, Rafique A, Mastaitis J, Lin C, Murphy AJ, Yancopoulos GD, Gromada J, Stitt T, Skeletal Muscle, 2015 · PMID 26457176

  The primary preclinical characterisation of REGN1033, including mRNA sequencing, immunohistochemistry and ex vivo force measurements in aged mice.

• Myostatin deficiency but not anti-myostatin blockade induces marked proteomic changes in mouse skeletal muscle Salzler RR, et al., Proteomics, 2016 · PMID 27214824

  Directly compares genetic myostatin deficiency with pharmacological blockade by REGN1033. Essential context for anyone reasoning about drug effects from the double-muscled phenotype.

• COURAGE (NCT06299098) - ClinicalTrials.gov record Regeneron Pharmaceuticals, ClinicalTrials.gov

  Source of the trial design, the 1005-patient actual enrolment, the eight-arm structure and the week-26 fat mass and lean mass co-primary endpoints.